Communiqués Monte Rosa Therapeutics, Inc.

Actions

GLUE

US61225M1027

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 28/06/2024			Varia. 5j.	Varia. 1 janv.
3,74 ^USD	+10,65%		+3,03%	-33,81%

27/06	Monte Rosa Therapeutics fait le point sur l'avancement du développement de MRT-2359 et MRT-6160	CI
14/06	Monte Rosa Therapeutics, Inc. Présente des données précliniques à EULAR 2024 démontrant le potentiel thérapeutique de MRT-6160 pour le traitement de la polyarthrite rhumatoïde.	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160	27/06	AQ
Monte Rosa Therapeutics : EULAR 2024 – MRT 6160, a VAV1 Directed Molecular Glue Degrader, Reduces Joint Inflammation and Autoantibody Production in a Collagen Induced Arthritis Autoimmune Disease Model	14/06	PU
Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis	14/06	AQ
Monte Rosa Therapeutics Announces Leadership Team Promotions	30/05	AQ
Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference	30/05	AQ
Monte Rosa Therapeutics : DDW 2024 – MRT 6160, a VAV1 Directed Molecular Glue Degrader, Inhibits Disease Progression in a T cell Transfer Mediated Colitis Model Concomitant with Reduced Calprotectin Expression	21/05	PU
Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease	21/05	AQ
Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering	16/05	AQ
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants	15/05	AQ
Monte Rosa Therapeutics : Corporate Presentation - May 2024	09/05	PU
Monte Rosa Therapeutics: Q1 Earnings Snapshot	09/05	AQ
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update	09/05	AQ
Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer	02/05	AQ
Monte Rosa Therapeutics : AACR 2024 – The GSPT1 Molecular Glue Degrader MRT-2359 Is Active against Prostate Cancer	03/04	PU
Monte Rosa Therapeutics: Q4 Earnings Snapshot	14/03	AQ
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	14/03	AQ
Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor	11/03	AQ
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences	31/01	AQ
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024	08/01	AQ
Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference	03/01	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Monte Rosa Therapeutics, Inc.

Actions

GLUE

US61225M1027

Communiqués

Filtres